Pluri Inc PLUR 深 沪
等待开盘 09-30 09:30:00 美东时间
1.009
+0.039
+4.01%
华盛通- 最 高1.0399
- 今 开0.9702
- 成交量 1.46万股
- 最 低 0.9702
- 昨 收 0.9701
- 总市值 1245.58万
- 52周最高 4.865
- 市盈率 静 --
- 换手率 0.12%
- 52周最低 0.90
- 委 比 -9.39%
- 总股本 1234.47万
- 历史最高 400.00
- 量 比 0.88
- 振 幅 7.18%
- 历史最低 0.90
- 每 手 1
- 风险率 0.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pluri prices $3.3 million offering
Pluri (PLUR) announced on Thursday that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 2.23M common shares (or...
08-27 20:39
Pluri Commences ~$3.3M Offering Of 2.229M Common Shares At $1.50 Per Share
Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri"), a biotechnology company, leveraging its proprietary three-dimensional ("3D") cell expansion platform across two principal business verticals: (i) Human Health & Longevity and (ii) FoodTech & Bio-Farming, today announced that it has entered into a secu...
08-27 20:04
Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor
Pluri Inc. announced it has entered into a securities purchase agreement with a healthcare-focused institutional investor to sell 2,228,940 Common Shares at $1.50 per share, raising approximately $3.3 million. Concurrently, Pluri will issue warrants for up to the same number of shares, exercisable at $1.65 per share, with a six-month vesting period and a five-and-a-half-year expiration. The offering is expected to close on August 28, 2026, with p...
08-27 12:00
Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment
Pluri Inc.'s majority-owned food-tech company, Ever After Foods (EAF), has acquired Fishway BV, a Belgium-based biotech company specializing in aquatic cell biology and animal-component-free (ACF) media development. The acquisition enhances EAF's bioprocess and manufacturing platform, expanding its capabilities for cultivated-protein applications and strengthening its European presence. Additionally, EAF secured a $2 million strategic investment ...
08-17 13:00
Pluri chairman raises stake above 30%; shares up
Pluri (PLUR) chairman Alejandro Weinstein has invested more than $17M in the company over the past year. His investments include a $1.25M advance investment made in June 2026 under an Advance Subscrip...
07-14 21:22
Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
Pluri Inc. Chairman Alejandro Weinstein has invested over $17 million in the company, holding more than 30% ownership. Weinstein's investment reflects confidence in Pluri's transition from platform development to commercial execution, particularly in the longevity sector. Pluri is advancing its U.S. commercialization strategy and has seen strong interest from U.S. parties for product purchases and collaborations. Weinstein, with over two decades ...
07-14 11:00
Pluri Secures Insider Advance Subscription to Boost Liquidity
The latest update is out from Pluri ( ($PLUR) ). On June 14, 2026, Pluri Inc. e...
06-23 05:07
Pluri Announces Completion Of Development And U.S. Cosmetic Product Listings For Two Flagship Regenerative Aesthetic Products, Regenativo+ And Placento+, Clearing Way For U.S. Commercial Launch
Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food
06-02 19:38
Pluri in Good-Faith Talks on EIB Loan Resolution
Pluri ( ($PLUR) ) just unveiled an announcement. Pluri Inc. previously entered ...
06-02 04:50
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.
04-30 20:01
